559 related articles for article (PubMed ID: 22036036)
1. Glutamatergic modulation of auditory information processing in the human brain.
Gunduz-Bruce H; Reinhart RM; Roach BJ; Gueorguieva R; Oliver S; D'Souza DC; Ford JM; Krystal JH; Mathalon DH
Biol Psychiatry; 2012 Jun; 71(11):969-77. PubMed ID: 22036036
[TBL] [Abstract][Full Text] [Related]
2. Haloperidol counteracts the ketamine-induced disruption of processing negativity, but not that of the P300 amplitude.
Oranje B; Gispen-de Wied CC; Westenberg HG; Kemner C; Verbaten MN; Kahn RS
Int J Neuropsychopharmacol; 2009 Jul; 12(6):823-32. PubMed ID: 19154656
[TBL] [Abstract][Full Text] [Related]
3. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia.
Umbricht D; Schmid L; Koller R; Vollenweider FX; Hell D; Javitt DC
Arch Gen Psychiatry; 2000 Dec; 57(12):1139-47. PubMed ID: 11115327
[TBL] [Abstract][Full Text] [Related]
4. Translating the Rosetta Stone of N-acetylcysteine.
Dean OM; Bush AI; Berk M
Biol Psychiatry; 2012 Jun; 71(11):935-6. PubMed ID: 22579303
[No Abstract] [Full Text] [Related]
5. Interactive effects of an N-methyl-d-aspartate receptor antagonist and a nicotinic acetylcholine receptor agonist on mismatch negativity: Implications for schizophrenia.
Hamilton HK; D'Souza DC; Ford JM; Roach BJ; Kort NS; Ahn KH; Bhakta S; Ranganathan M; Mathalon DH
Schizophr Res; 2018 Jan; 191():87-94. PubMed ID: 28711472
[TBL] [Abstract][Full Text] [Related]
6. Glutamatergic deficit and schizophrenia-like negative symptoms: new evidence from ketamine-induced mismatch negativity alterations in healthy male humans.
Thiebes S; Leicht G; Curic S; Steinmann S; Polomac N; Andreou C; Eichler I; Eichler L; Zöllner C; Gallinat J; Hanganu-Opatz I; Mulert C
J Psychiatry Neurosci; 2017 Jun; 42(4):273-283. PubMed ID: 28556775
[TBL] [Abstract][Full Text] [Related]
7. The effects of ketamine on the mismatch negativity (MMN) in humans - A meta-analysis.
Rosburg T; Kreitschmann-Andermahr I
Clin Neurophysiol; 2016 Feb; 127(2):1387-1394. PubMed ID: 26699665
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia.
Roser P; Haussleiter IS; Chong HJ; Maier C; Kawohl W; Norra C; Juckel G
Psychopharmacology (Berl); 2011 Dec; 218(4):611-20. PubMed ID: 21590281
[TBL] [Abstract][Full Text] [Related]
9. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients.
Lavoie S; Murray MM; Deppen P; Knyazeva MG; Berk M; Boulat O; Bovet P; Bush AI; Conus P; Copolov D; Fornari E; Meuli R; Solida A; Vianin P; Cuénod M; Buclin T; Do KQ
Neuropsychopharmacology; 2008 Aug; 33(9):2187-99. PubMed ID: 18004285
[TBL] [Abstract][Full Text] [Related]
10. Deviance-elicited changes in event-related potentials are attenuated by ketamine in mice.
Ehrlichman RS; Maxwell CR; Majumdar S; Siegel SJ
J Cogn Neurosci; 2008 Aug; 20(8):1403-14. PubMed ID: 18303985
[TBL] [Abstract][Full Text] [Related]
11. Ketamine effects on brain function--simultaneous fMRI/EEG during a visual oddball task.
Musso F; Brinkmeyer J; Ecker D; London MK; Thieme G; Warbrick T; Wittsack HJ; Saleh A; Greb W; de Boer P; Winterer G
Neuroimage; 2011 Sep; 58(2):508-25. PubMed ID: 21723949
[TBL] [Abstract][Full Text] [Related]
12. Effect of ketamine on the neuromagnetic mismatch field in healthy humans.
Kreitschmann-Andermahr I; Rosburg T; Demme U; Gaser E; Nowak H; Sauer H
Brain Res Cogn Brain Res; 2001 Aug; 12(1):109-16. PubMed ID: 11489614
[TBL] [Abstract][Full Text] [Related]
13. Effects of Acute Ketamine Infusion on Visual Working Memory: Event-Related Potentials.
Koychev I; William Deakin JF; El-Deredy W; Haenschel C
Biol Psychiatry Cogn Neurosci Neuroimaging; 2017 Apr; 2(3):253-262. PubMed ID: 29528296
[TBL] [Abstract][Full Text] [Related]
14. Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing-study on P300 and mismatch negativity in healthy volunteers.
Bravermanová A; Viktorinová M; Tylš F; Novák T; Androvičová R; Korčák J; Horáček J; Balíková M; Griškova-Bulanova I; Danielová D; Vlček P; Mohr P; Brunovský M; Koudelka V; Páleníček T
Psychopharmacology (Berl); 2018 Feb; 235(2):491-503. PubMed ID: 29302713
[TBL] [Abstract][Full Text] [Related]
15. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.
Krystal JH; Abi-Saab W; Perry E; D'Souza DC; Liu N; Gueorguieva R; McDougall L; Hunsberger T; Belger A; Levine L; Breier A
Psychopharmacology (Berl); 2005 Apr; 179(1):303-9. PubMed ID: 15309376
[TBL] [Abstract][Full Text] [Related]
16. Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis.
Heekeren K; Daumann J; Neukirch A; Stock C; Kawohl W; Norra C; Waberski TD; Gouzoulis-Mayfrank E
Psychopharmacology (Berl); 2008 Jul; 199(1):77-88. PubMed ID: 18488201
[TBL] [Abstract][Full Text] [Related]
17. The effects of a sub-anaesthetic dose of ketamine on human selective attention.
Oranje B; van Berckel BN; Kemner C; van Ree JM; Kahn RS; Verbaten MN
Neuropsychopharmacology; 2000 Mar; 22(3):293-302. PubMed ID: 10693157
[TBL] [Abstract][Full Text] [Related]
18. Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers.
Umbricht D; Koller R; Vollenweider FX; Schmid L
Biol Psychiatry; 2002 Mar; 51(5):400-6. PubMed ID: 11904134
[TBL] [Abstract][Full Text] [Related]
19. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.
Malhotra AK; Pinals DA; Weingartner H; Sirocco K; Missar CD; Pickar D; Breier A
Neuropsychopharmacology; 1996 May; 14(5):301-7. PubMed ID: 8703299
[TBL] [Abstract][Full Text] [Related]
20. Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments.
Schmidt A; Bachmann R; Kometer M; Csomor PA; Stephan KE; Seifritz E; Vollenweider FX
Neuropsychopharmacology; 2012 Mar; 37(4):865-75. PubMed ID: 22030715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
